Literature DB >> 11714823

Fc receptor-mediated immunity against Bordetella pertussis.

M E Rodriguez1, S M Hellwig, D F Hozbor, J Leusen, W L van der Pol, J G van de Winkel.   

Abstract

The relevance of specific Abs for the induction of cellular effector functions against Bordetella pertussis was studied. IgG-opsonized B. pertussis was efficiently phagocytosed by human polymorphonuclear leukocytes (PMN). This process was mediated by the PMN IgG receptors, FcgammaRIIa (CD32) and FcgammaRIIIb (CD16), working synergistically. Furthermore, these FcgammaR triggered efficient PMN respiratory burst activity and mediated transfer of B. pertussis to lysosomal compartments, ultimately resulting in reduced bacterial viability. Bacteria opsonized with IgA triggered similar PMN activation via FcalphaR (CD89). Simultaneous engagement of FcalphaRI and FcgammaR by B. pertussis resulted in increased phagocytosis rates, compared with responses induced by either isotype alone. These data provide new insights into host immune mechanisms against B. pertussis and document a crucial role for Ig-FcR interactions in immunity to this human pathogen.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714823     DOI: 10.4049/jimmunol.167.11.6545

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Humoral immunity against Bordetella pertussis: antibodies or B cells?

Authors:  María Eugenia Rodriguez; W-Ludo van der Pol
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

2.  Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  Paula S Mobberley-Schuman; Alison A Weiss
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Kari Torkildsen Brandsdal; Bjørn Peter Berdal; Erja M Aleksandersen; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2007-05-16

4.  Intracellular trafficking of Bordetella pertussis in human macrophages.

Authors:  Yanina A Lamberti; Jimena Alvarez Hayes; Maria L Perez Vidakovics; Eric T Harvill; Maria Eugenia Rodriguez
Journal:  Infect Immun       Date:  2010-01-11       Impact factor: 3.441

5.  Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Authors:  Audun Aase; Tove Karin Herstad; Samuel Merino; Merete Bolstad; Synne Sandbu; Hilde Bakke; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2011-06-15

6.  Bordetella parapertussis survives inside human macrophages in lipid raft-enriched phagosomes.

Authors:  Juan Gorgojo; Eric T Harvill; Maria Eugenia Rodríguez
Journal:  Infect Immun       Date:  2014-09-29       Impact factor: 3.441

7.  Bordetella parapertussis survives the innate interaction with human neutrophils by impairing bactericidal trafficking inside the cell through a lipid raft-dependent mechanism mediated by the lipopolysaccharide O antigen.

Authors:  Juan Gorgojo; Yanina Lamberti; Hugo Valdez; Eric T Harvill; Maria Eugenia Rodríguez
Journal:  Infect Immun       Date:  2012-10-01       Impact factor: 3.441

8.  Decreased leukocyte accumulation and delayed Bordetella pertussis clearance in IL-6-/- mice.

Authors:  Xuqing Zhang; Tania Goel; Laura L Goodfield; Sarah J Muse; Eric T Harvill
Journal:  J Immunol       Date:  2011-03-11       Impact factor: 5.422

9.  O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies.

Authors:  Xuqing Zhang; Maria Eugenia Rodríguez; Eric T Harvill
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

10.  The O antigen is a critical antigen for the development of a protective immune response to Bordetella parapertussis.

Authors:  Xuqing Zhang; Elizabeth M Goebel; Maria Eugenia Rodríguez; Andrew Preston; Eric T Harvill
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.